• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
  • Contact

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Sponsored Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Misonix Reports a 29% and 24% Increase in Revenue for the Second Quarter and Six Months Fiscal 2012 Financial Results


News provided by

Misonix, Inc.

Feb 08, 2012, 08:30 ET

Share this article

Share this article


FARMINGDALE, N.Y., Feb. 8, 2012 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a medical device company that designs, manufactures, and markets innovative therapeutic ultrasonic products worldwide for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery and other surgical and medical applications, today reported financial results for the second fiscal quarter and six months ending December 31, 2011.  Michael A. McManus Jr., President and Chief Executive Officer, and Richard Zaremba, Senior Vice President and Chief Financial Officer, will host a conference call Wednesday, February 8, 2012 at 4:30 pm EASTERN to discuss the Company's second quarter results.

The Company also reported the following financial and operational achievements:

  • A 29% increase in revenue for the three months ending December 31, 2011 compared with the same period ending December 31, 2010.
  • A 24% increase in revenue for the six months ending December 31, 2011 compared with the same period ending December 31, 2010.
  • Gross profits as a percentage of revenue were 63.9% for the three months ending December 31, 2011 compared with 62.4% for the three months ending December 31, 2010.
  • Gross profits as a percentage of revenue were 59.6% for the six months ending December 31, 2011 compared with 58.6% for the six months ending December 31, 2010.
  • Net income reported from continuing operations of $228,000 for the three months ending December 31, 2011 compared with a loss of $505,000 for the same period in fiscal 2011.
  • Sold Laboratory and Forensic Safety Products business for $1.5 million plus potential $500,000 over the next 3 years.

Revenue for the three months ended December 31, 2011 was $3.6 million, a 29% increase when compared with $2.8 million for the same period in fiscal 2011.  The increase in medical device products sales was primarily attributable to sales of the Company's BoneScalpel™ and Neuroaspirator products.

Gross profit as a percentage of sales (gross profit percentage) was 63.9% for the three months ended December 31, 2011 compared with 62.4% for the three months ended December 31, 2010.  

The Company reported income from continuing operations of $228,000 or $0.03 per diluted share for the three months ended December 31, 2011 compared with a loss of $505,000 or $(0.07) loss for the same period in fiscal 2011.  The Company reported net income for the three months ended December 31, 2011 of $1.0 million, or $0.15 per share, compared to a net loss of $536,000, or $(0.08) per share, for the three months ended December 31, 2010.

Revenue for the six months ended December 31, 2011 was $6.8 million, a 24% increase when compared with $5.5 million for the same period in fiscal 2011.

The Company reported net income of $136,000 or $0.02 per share for the six months ended  December 31, 2011 compared with a net loss of $1.6 million or $(0.22) per share for the six months ended December 31, 2010.

Commenting on Misonix's financial and operating results, Michael A. McManus Jr., President and Chief Executive Officer, said, "We are pleased at the growth of our revenues and continued trends in gross margins particularly with respect to our core medical device products. We continue to reduce G&A expenses, having made additional progress this quarter. We will continue to manage our administrative expenses prudently, while supporting investments in product development and sales and marketing.  In late October, we announced the sale of our Laboratory and Forensic Safety Products business.  This sale of a non-core business completes our strategy to focus exclusively on medical device products and enabled us to strengthen our balance sheet with an additional $1.5 million and an opportunity to receive an additional $500,000 in total over the next three years.  Our plan is to use the proceeds to continue to invest in sales and marketing efforts in our medical device business.  

"We remain committed to our strategic vision and belief that increased medical device sales through our proprietary sales channels, our emphasis on high margin disposables, a broader geographic reach and development of new surgical applications and technology will strengthen and grow the Company over time."

Conference Call:

Misonix management will host a conference call and webcast on Wednesday, February 8, 2012 at 4:30 pm EASTERN to discuss second quarter results.

Shareholders and other interested parties may participate in the conference call by dialing 877-317-6789 (domestic) or 412-317-6789 (international), a few minutes before the start of the call. A simultaneous webcast will be available via Misonix's website at www.misonix.com. The call will be archived on the Company's website for at least 90 days.

A recording of the live-call will be available for three days at 877-344-7529 or 412-317-0088, confirmation #10009914.

About Misonix:

Misonix, Inc. designs, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships,  regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  The Company disclaims any obligation to update its forward-looking relationships.

Misonix Contact:

Investor Relations Contact:

Richard Zaremba

Joe Diaz, Lytham Partners

631-694-9555

602-889-9700

[email protected]

[email protected]

MISONIX, INC. And Subsidiaries


Consolidated Balance Sheets







December 31, 2011


June 30, 2011



Unaudited


Derived from audited





financial statements

Assets





Current Assets:





  Cash and cash equivalents


$6,696,617


$6,881,093

  Accounts receivable, less allowance





       for doubtful accounts of $140,739 and





       $115,739, respectively


1,875,984


2,085,972

  Inventories, net


3,658,409


3,130,207

  Prepaid expenses and other current assets


172,224


374,472

  Note receivable


410,500


210,000

  Current assets of discontinued operations


498,234


857,095

Total current assets


13,311,968


13,538,839






Property, plant and equipment, net


958,664


969,336

Goodwill


1,701,094


1,701,094

Other assets


1,748,338


2,127,194

Assets of discontinued operations


-


21,859

Total assets


$17,720,064


$18,358,322






Liabilities and stockholders' equity





Current liabilities:





  Accounts payable


$               1,041,124


$                      1,110,694

  Accrued expenses and other current liabilities


1,109,455


1,969,078

  Liabilities of discontinued operations


228,675


225,864

Total current liabilities


2,379,254


3,305,636






Deferred income


$                  139,253


$                         161,360

Deferred lease liability


18,519


14,043

Total liabilities


2,537,026


3,481,039






Commitments and contingencies










Stockholders' equity:





  Capital stock, $0.01 par value - shares authorized 20,000,000; 7,079,170





  issued and 7,001,370 outstanding, respectively


70,792


70,792

  Additional paid-in capital


25,957,578


25,787,960

  Accumulated deficit


(10,432,908)


(10,569,045)

  Treasury stock, 77,800 shares


(412,424)


(412,424)

Stockholders' equity


15,183,038


14,877,283

Total liabilities and stockholders' equity


$17,720,064


$18,358,322

MISONIX, INC. And Subsidiaries






Consolidated Statements of Operations






Unaudited













Three Months Ended


Six Months Ended


December 31,


December 31,


2011

2010


2011

2010

Net sales

$3,550,535

$2,762,556


$6,767,734

$5,454,824







Cost of goods sold

1,281,561

1,039,307


2,734,968

2,259,004







Gross profit

2,268,974

1,723,249


4,032,766

3,195,820







Selling expenses

1,194,045

907,693


2,374,297

1,728,207

General and administrative expenses

1,082,385

1,109,482


2,250,205

2,327,287

Research and development expenses

303,702

352,161


613,676

733,438

Total operating expenses

2,580,132

2,369,336


5,238,178

4,788,932







Loss from operations

(311,158)

(646,087)


(1,205,412)

(1,593,112)







Total other income

331,871

144,682


427,099

346,272













Income (loss) from continuing operations before  income taxes

20,713

(501,405)


(778,313)

(1,246,840)







Income tax (benefit) expense

(207,233)

4,000


(202,273)

42,100







Net income (loss) from continuing operations

227,946

(505,405)


(576,040)

(1,288,940)







Discontinued operations:






Net loss from discontinued operations, net of tax benefit of $130,517,$0,$130,517 and $0, respectively

(126,225)

(30,761)


(206,181)

(265,072)

Net gain from sale of discontinued operations net of tax expense of $532,268,$0,$532,268 and $0, respectively

918,358

-


918,358

-

Net income (loss) from discontinued operations

792,133

(30,761)


712,177

(265,072)

Net income (loss)

$1,020,079

($536,166)


$136,137

($1,554,012)







Net income (loss) per share from continuing operations-Basic

$0.03

($0.07)


($0.08)

($0.18)

Net income (loss) per share from discontinued operations-Basic

0.11

(0.01)


0.10

(0.04)

Net income (loss) per share-Basic

$0.15

($0.08)


$0.02

($0.22)







Net income (loss) per share from continuing operations-Diluted

$0.03

($0.07)


($0.08)

($0.18)

Net income (loss) per share from discontinued operations-Diluted

0.11

(0.01)


0.10

(0.04)

Net income (loss) per share-Diluted

$0.15

($0.08)


$0.02

($0.22)







Weighted average common shares-basic

7,001,370

7,001,370


7,001,370

7,001,370







Weighted average common shares-diluted

7,001,370

7,001,370


7,001,370

7,001,370

SOURCE Misonix, Inc.

Modal title

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2023 Cision US Inc.